title: Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer.
abstract: Estrogen receptor α (ERα) is a critical prognostic and predictive biomarker in breast cancer. ERα expression is used to determine whether patients should be treated with endocrine therapy, which is designed to block ERα signaling. Endocrine therapy given for 5-10 y after surgery improves progression-free and overall survival for patients with ER-positive primary breast cancer. However, disease recurrence and development of metastatic disease can occur despite appropriate treatment with endocrine therapy. Thus, a functional test performed at the time of initial diagnosis that can identify which patients would do well with endocrine therapy alone versus those who require adjuvant chemotherapy would be impactful for improving patient outcomes.
authors.affiliation: Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; and.
authors.forename: Amy M
authors.initials: AM
authors.lastname: Fowler
authors.affiliation: Department of Medicine, University of Washington, Seattle, Washington hmlinden@uw.edu.
authors.forename: Hannah M
authors.initials: HM
authors.lastname: Linden
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D004958:Estradiol / Q000031:analogs & derivatives / Q000378:metabolism; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D000072078:Positron Emission Tomography Computed Tomography; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000378:metabolism*
chemical_list: D011960:Receptors, Estrogen; D004958:Estradiol; C043436:16-fluoroestradiol
keywords: 18F-fluoroestradiol; breast cancer; estrogen receptor; molecular imaging; neoadjuvant therapy